Home » News » AIM News » Oncimmune Holdings plc Announces Registration of EarlyCDT®-Lung in Columbia
Oncimmune Holdings Plc

Oncimmune Holdings plc Announces Registration of EarlyCDT®-Lung in Columbia

Oncimmune Holdings plc (LON: ONC), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, has today announced its distributor in Columbia, Valentech International LLC, has obtained regulatory approval for the sale of EarlyCDT-Lung.

The company has an existing signed distribution agreement with Valentech for Brazil and Columbia. Columbia has a population of 49.7 million and an estimated 12 in every 100,000 of the population die of lung cancer every year.

ONC is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both immuno-oncology and autoimmune disease. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body’s natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune’s tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally.

Oncimmune Holdings plc was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT-Lung and EarlyCDT-Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT-Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market of the London Stock Exchange in May 2016.